Therapy News and Research

RSS

Deep-brain stimulation may stop uncontrollable shaking in patients with Parkinson's

Deep-brain stimulation (DBS) may stop uncontrollable shaking in patients with Parkinson's disease and essential tremor by imposing its own rhythm on the brain, according to two studies published recently by University of Alabama at Birmingham researchers in the journal Movement Disorders.

29 Aug 2012

Novelos expects to submit CLR1502 IND with FDA for non-invasive tumor imaging

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it is developing CLR1502 (GLOW2), a preclinical cancer-targeted optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.

29 Aug 2012

Study to investigate how breast cancer patients might benefit from exercise

Researchers in Edmonton and Calgary want to recruit 1,500 breast cancer patients over the next decade to find out how exercise and fitness affects cancer survival and recovery.

29 Aug 2012

Viewpoints: Adding a middle man to Medicare; Circumcision wars; Who is an extremist on abortion?

Bear in mind that health expenses will still have to be mainly paid for by some kind of insurance; that's in the nature of medical care, with its high but unpredictable cost. So what we're doing here is replacing government insurance with a program that gives people money to buy private insurance - that is, adding an extra layer of middlemen.

29 Aug 2012

Acorda’s GGF2 can improve erectile function after cavernous nerve damage

Acorda Therapeutics, Inc. announced data from a preclinical study showed that treatment with Glial Growth Factor 2 (GGF2) improved erectile function in an animal model following a cavernous nerve (CN) injury, a common complication of prostate surgery.

29 Aug 2012

FFR-guided PCI plus medical therapy reduce need for urgent revascularization in CAD patients

Patients with stable coronary artery disease (CAD) had a lower need for urgent revascularisation when receiving fractional flow reserve (FFR)-guided PCI plus the best available medical therapy (MT) than when receiving MT alone. The results, from a final analysis of the FAME 2 trial, were presented today during a Hot Line session of ESC Congress 2012 in Munich.

29 Aug 2012

Risk of stroke after myocardial infarction seems to decrease with improvements in coronary care

The analysis of data from two Swedish registries was presented by Dr Anders Ulvenstam, and suggests that the reduction is due to improvements in AMI care.

29 Aug 2012

NUI Galway project hopes to deliver cost effective tool for rapid diagnosis of pneumonia

Researchers at NUI Galway are involved in a new European project which hopes to deliver a cost effective tool for the speedy diagnosis of infections such as pneumonia. The test would reduce diagnosis time from days to hours, so that the appropriate treatments can be administered as early as possible for the best possible outcome.

29 Aug 2012

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced top-line results from a Phase II clinical study of Archexin, its clinical-stage oncology drug candidate.

29 Aug 2012

St. Jude’s EnligHTN renal denervation system safe and effective in treating resistant hypertension

St. Jude Medical, Inc., a global medical device company, today announced that interim data demonstrated the company's EnligHTN renal denervation system is safe and effective for the treatment of resistant hypertension.

29 Aug 2012

Altheus Therapeutics initiates enrollment in Zoenasa Phase 2 study for ulcerative colitis

Altheus Therapeutics announced today it has randomized its first patient in a comparator-controlled Phase 2 efficacy study of Zoenasa, a novel combination therapy for ulcerative colitis (UC).

29 Aug 2012

Eplerenone shown to reduce cumulative heart failure hospitalisations

Pfizer Inc. (NYSE: PFE) announced results from a new post-hoc analysis of the EMPHASIS-HF trial showing statistically significant reductions in rates of cumulative heart failure (HF) hospitalisations in patients with HF treated with eplerenone compared with placebo on a background of standard optimal therapy.1 The results were presented at The European Society of Cardiology Congress (ESC) in Munich.

28 Aug 2012

Study raises cautionary note about preferential use of endovascular technique for ruptured AAA

A new study raises a cautionary note about the increasing use of a minimally invasive procedure to repair ruptured abdominal aortic aneurysms, according to vascular surgeon Dr. Jae Sung Cho of Loyola University Medical Center.

28 Aug 2012

Transcatheter renal denervation reduces blood pressure in real world patients

Renal denervation successfully treats patients with resistant hypertension in real world patient populations, according to a study presented at ESC Congress 2012. The findings were presented by Dr Darren Mylotte from France.

28 Aug 2012

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

28 Aug 2012

Global platelet reactivity effectively identifies ACS patients at high risk of ischemic events

Global platelet reactivity is more effective than responsiveness to clopidogrel in identifying acute coronary syndrome (ACS) patients at high risk of ischemic events, according to research presented at the ESC Congress today. The results from the RECLOSE 2-ACS study were presented by Dr Rossella Marcucci from Italy.

28 Aug 2012

Friedreich Ataxia Research Alliance, USF ARC to host ‘Understanding a Cure’ symposium

Scientists, clinicians and patients will gather at the University of South Florida's Center for Advanced Medical Learning and Simulation (CAMLS) in downtown Tampa Sept. 6 to share research insights and energize the search for a cure for Friedreich's ataxia and related disorders.

28 Aug 2012

Major decline in early mortality for STEMI patients: French registries

Data from four French nationwide registries of STEMI (ST-elevation myocardial infarction) patients initiated five years apart and covering more than 15 years show that mortality rate decreased by 68% over this period, from 13.7% to 4.4%. Around one quarter of this mortality reduction could be attributed to a change in patient characteristics.

28 Aug 2012

Positive results from CardioKinetix’s Parachute device clinical trial on ischemic heart failure

CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced clinical results showing meaningful and sustained low clinical events for patients with ischemic heart failure three years following Percutaneous Ventricular Restoration (PVR) therapy with the first-of-its-kind catheter-based Parachute™ Ventricular Partitioning Device.

28 Aug 2012

Community-based pharmacists could provide added resource in identifying knee OA

Canadian researchers have determined that community-based pharmacists could provide an added resource in identifying knee osteoarthritis (OA). The study, published in Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), represents the first evidence supporting a collaborative approach to managing knee OA.

28 Aug 2012

Therapy News and Research

Deep-brain stimulation may stop uncontrollable shaking in patients with Parkinson's

Novelos expects to submit CLR1502 IND with FDA for non-invasive tumor imaging

Study to investigate how breast cancer patients might benefit from exercise

Viewpoints: Adding a middle man to Medicare; Circumcision wars; Who is an extremist on abortion?

Acorda’s GGF2 can improve erectile function after cavernous nerve damage

FFR-guided PCI plus medical therapy reduce need for urgent revascularization in CAD patients

Risk of stroke after myocardial infarction seems to decrease with improvements in coronary care

NUI Galway project hopes to deliver cost effective tool for rapid diagnosis of pneumonia

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

St. Jude’s EnligHTN renal denervation system safe and effective in treating resistant hypertension

Altheus Therapeutics initiates enrollment in Zoenasa Phase 2 study for ulcerative colitis

Eplerenone shown to reduce cumulative heart failure hospitalisations

Study raises cautionary note about preferential use of endovascular technique for ruptured AAA

Transcatheter renal denervation reduces blood pressure in real world patients

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Global platelet reactivity effectively identifies ACS patients at high risk of ischemic events

Friedreich Ataxia Research Alliance, USF ARC to host ‘Understanding a Cure’ symposium

Major decline in early mortality for STEMI patients: French registries

Positive results from CardioKinetix’s Parachute device clinical trial on ischemic heart failure

Community-based pharmacists could provide added resource in identifying knee OA

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News